Business
INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020
Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time LA JOLLA, Calif., July 09,
About this update from Inmune Bio Inc.
[{"type":"text","content":"Data Focused on Biomarkers of Neuroinflammation will be Topic of Key Opinion Leaders Call Set for July 14 at 8:00 AM Eastern Time\nLA JOLLA, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that next week it will report interim data from its Phase Ib clinical study of XPro1595 in Alzheimer’s disease. In addition, INmune will host on July 14 a key opinion leader webinar in which the data will be discussed. The webinar will take place prior to AAIC 2020, the world’s largest and most influential international meeting dedicated to advancing dementia science. AAIC 2020 will run virtually July 27-31. \n XPro1595 is a selective inhibitor of soluble Tumor Necrosis Factor, a key inflammatory cytokine implicated in causing neuroinflammation in patients with Alzheimer’s disease. The Phase Ib multi-center, open-label, multi-dose study is currently enrolling patients with Alzheimer’s disease who express biomarkers of inflammation. The goal of the proof-of-biology trial is to determine if XPro1595 can reduce neuroinflammatory biomarkers following 12 weeks of treatment. Results will inform the design of a proof-of-concept study using XPro1595 to treat patients with Alzheimer’s disease with biomarkers of inflammation. The study is supported by a $1M Part the Cloud Award from the Alzheimer’s Association. The call will start with a brief presentation of the data by RJ Tesi, M.D., CEO of INmune Bio, and CJ Barnum, Ph.D., Director of Neuroscience at INmune Bio, followed by a panel discussion with the following participants: Rosalyn Lai, M.D., a Psychiatrist and Principal Investigator at KaRa MINDS in Sydney, Australia, which is a site enrolling patients in the study.Max Descoteaux, Ph.D., Professor, Computer Science Department, Sherbrooke University, CSO of Imeka and an expert in imaging brain connectivity, from state-of-the-art diffusion MRI acquisition, reconstruction, tractography and processing to visualization.Judith Jaeger Ph.D., President and Principal Scientist of CognitionMetrics, LLC, an internationally recognized cognitive neuropsychologist. Malu Tansey, Ph.D., Professor of Neuroscience and Neurology at the Medical College of the University of Florida, a...